Emilia Javorsky
speaker
1,653 appearances
2 recordings
1 series
first heard Mar 2026
last heard 20 Mar
Emilia Javorsky’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Mar 2026 with 2.
Appearances
These failures reveal a pattern, consistently overestimating the value of intelligence and technology, while greatly underestimating the complexity, data challenges, and institutional complexities of medicine.
IBM's Watson Health serves as perhaps the most cautionary tale.
At a 2017 Health IT conference, IBM CEO Ginni Rometty told attendees that AI is real, it's mainstream, it's here, and it can change almost everything about healthcare, promising to usher in a medical golden age.
After $5 billion invested, Watson Health was sold for parts in 2022, with minimal real-world impact.
As Professor Gary Marcus observed, Watson was a great system for Jeopardy, but it didn't mean you could expect the same technology to solve cancer, too.
The fundamental problem was not insufficient AI capability, but a misunderstanding of healthcare's data landscape and clinical workflows.
Microsoft's Health Vault, launched with fanfare as a platform to revolutionize health records, was shuttered in 2019 after failing to gain meaningful market adoption.
Google's life sciences spinoff Verily, despite $2.5 billion in investment over six years, was already being called a case study in the power and the limitations of tech industry hubris by 2019.
The company's ambitious efforts to develop comprehensive health monitoring and intervention tools floundered on the complexity of translating sensor data into clinically actionable insights.
Google's longevity spinoff, Calico, represents perhaps the most striking example of the intelligence illusion.
Calico was founded in 2013 with the explicit mission to solve aging and extend human lifespan.
Radical life extension is another superintelligence promise.
Superintelligence will not only cure cancer, but extend our lifespans by 1,400 years or even longer, through some yet-to-be-defined magic.
Calico attracted top scientific talent and significant funding.
The company operated in stealth for years, the assumption being that Google-scale intelligence and resources applied to biology would yield breakthroughs.
In 2025, the company publicly revealed that its lead drug candidate for ALS had failed in clinical trials, 12 years and billions of dollars later, with little to show for the investment.
The failure illustrates a fundamental misunderstanding that intelligence and capital alone can overcome the biological complexity and translational challenges inherent in therapeutic development.
Haven, the joint healthcare venture from Amazon, Berkshire Hathaway, and J.P.
Morgan, represented unprecedented corporate muscle applied to healthcare reform.
If anyone could break through healthcare's ossified structures, surely it would be three of the world's most powerful companies working in concert.
Showing 761–780 of 1,653 · page 39 of 83
← Previous
Next →